[From high content screening to target deconvolution: New insights for phenotypic approaches].

The advent of the molecular biology and the completion of the human genome sequencing prompted the pharmaceutical industry to progressively implement target-centric drug discovery strategies. However, concerns regarding the research and development productivity during the last ten years, combined with technological developments in high-content screening, automation, image analysis and artificial intelligence triggered a renewed interest for the phenotypic drug discovery approaches. Target-centric and phenotypic approaches are more and more considered complementary, hence, positioning the target deconvolution on the critical path. This review analyzes the evolution of the target-centric and phenotypic approaches, focusing more specifically on the high-content screening and the target deconvolution technologies currently available.

[1]  M. Mckee,et al.  Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. , 2020, JAMA.

[2]  Sepp Hochreiter,et al.  Accurate Prediction of Biological Assays with High-Throughput Microscopy Images and Convolutional Networks , 2019, J. Chem. Inf. Model..

[3]  Thierry Dorval,et al.  Filling the drug discovery gap: is high-content screening the missing link? , 2018, Current opinion in pharmacology.

[4]  Jun Sese,et al.  Compound‐protein interaction prediction with end‐to‐end learning of neural networks for graphs and sequences , 2018, Bioinform..

[5]  E. Baloglu,et al.  Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes , 2018, Nature Communications.

[6]  T. Cash-Mason,et al.  GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.

[7]  S. Nijman,et al.  Functional genomics to uncover drug mechanism of action. , 2015, Nature chemical biology.

[8]  P. Brodin,et al.  [High content screening in chemical biology: overview and main challenges]. , 2015, Medecine sciences : M/S.

[9]  Amanda N Haile,et al.  Supplemental Figure 1 , 2014 .

[10]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[11]  Adrian V. Lee,et al.  Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery , 2014, PloS one.

[12]  C. Wiesmann,et al.  The discovery of first-in-class drugs: origins and evolution , 2014, Nature Reviews Drug Discovery.

[13]  Wei Zheng,et al.  Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.

[14]  Caroline Barette,et al.  [Phenotypic screens or one stone to kill two birds: discover the target and its pharmacological regulator]. , 2013, Medecine sciences : M/S.

[15]  E. Berg,et al.  Neoclassic Drug Discovery , 2013, Journal of biomolecular screening.

[16]  P. Young.  Perspective on the Discovery and Scientific Impact of p38 MAP Kinase , 2013, Journal of biomolecular screening.

[17]  R. Abagyan,et al.  Compound activity prediction using models of binding pockets or ligand properties in 3D. , 2012, Current topics in medicinal chemistry.

[18]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[19]  K. Johnsson,et al.  A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. , 2011, Nature chemical biology.

[20]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[22]  M. Kirschner,et al.  Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. , 2006, Chemistry & biology.

[23]  Lin Tang,et al.  Roscovitine Targets, Protein Kinases and Pyridoxal Kinase*[boxs] , 2005, Journal of Biological Chemistry.

[24]  S. Haggarty,et al.  Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Lani F. Wu,et al.  Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.

[26]  So-Jung Park,et al.  A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. , 2004, Chemistry & biology.

[27]  Sebastian Meier-Ewert,et al.  A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. , 2004, Chemistry & biology.

[28]  B. Kreider,et al.  Drug receptor identification from multiple tissues using cellular-derived mRNA display libraries. , 2002, Chemistry & biology.

[29]  D. Austin,et al.  Display cloning: functional identification of natural product receptors using cDNA-phage display. , 1999, Chemistry & biology.

[30]  E J Licitra,et al.  A three-hybrid system for detecting small ligand-protein receptor interactions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Brett Lomenick.  Small Molecule Target Identification using Drug Affinity Responsive Target Stability (DARTS) , 2013 .